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Pharmacy Technicians-in-Training
As many of you are already aware, all pharmacy technicians-
in-training are now required to have a license before working in 
a pharmacy. Regulation 247 Code of Massachusetts Regulation 
8.00 was updated to track all persons training to become phar-
macy technicians, and this new license type is generating a high 
volume of applications. Massachusetts Board of Registration 
in Pharmacy staff has been working diligently to process them 
in a timely manner, and the Board wants to assure its licensees 
that it will always do its best to expedite the process. 
Until the trainee license has been obtained, new technician 
trainees may undertake training fundamentals as long as they 
do not require access to drugs or assist in the prescription fill-
ing process.
For example, in a retail setting, neither a license nor being 
counted in the staffing ratio is required while learning how 
to operate the cash register. Other potential actions that can 
be completed while awaiting a license would be learning the 
computer system, becoming familiar with company policies, 
Health Insurance Portability and Accountability Act training, 
and other company “start-up” procedures.
The Board apologizes in advance if the wait for any license 
is longer than expected. If an applicant has not received license 
verification after 7-10 days, please do not hesitate to contact the 
Board so that we can investigate your inquiry. As a reminder, 
technician trainees may take the licensure exam and apply for 
licensure after 500 hours, but must do so before the license 
expires. The technician-in-training license is valid for one year 
or 1,500 hours, whichever comes first. 
Compounding of Copies of a Commercially 
Available Drug Product
Massachusetts General Law Chapter 112 Section 39D de-
fines “compounding” as the preparation, mixing, assembling, 
packaging, or labeling of one or more active ingredients with 
one or more other substances in order to create a final drug 
preparation that meets a unique medical need of an individual 
patient. That compounded drug preparation must demonstrate 
a significant difference from the comparable commercially 
available drug and is required to meet a documented medical 
need as determined by the prescriber. This medical need must 
be noted on the prescription. Cost saving is not considered a 
“significant difference” to justify compounding. One example 
of permitted compounding would be a product that must be 
compounded without a preservative or other allergen for a 
specific patient’s use. 
Federal guidance, “Compounded Drug Products That Are 
Essentially Copies of a Commercially Available Drug Product 
Under Section 503A of the Federal Food, Drug, and Cosmetic 
Act” also restricts the compounding of drug products that are 
essentially copies of a commercially available drug product. 
Food and Drug Administration (FDA) considers a compounded 
drug product to be essentially a copy of a commercially avail-
able drug product if:
1. The compounded drug product has the same active
pharmaceutical ingredient(s) (API) as the commercially
available drug product;
2. The API(s) have the same, similar, or an easily substitut-
able dosage strength; and
3. The commercially available drug product can be used
by the same route of administration as prescribed for
the compounded drug.
FDA does not consider a drug product to be commercially 
available if the approved product is no longer marketed or the 
drug product appears on the FDA drug shortage list. If the 
drug must be compounded due to one of these circumstances, 
the compounder should note on the prescription the reason for 
compounding as well as the date the shortage list was consulted.
Board staff has recently received inquiries on the compound-
ing of oral vancomycin solution from injectable vials. Now that 
oral vancomycin suspension has been FDA approved and is a 
commercially available product, oral vancomycin should no 
longer be compounded.
Power Loss
It is advisable to establish and implement a contingency plan 
in the event of a power loss in the pharmacy. The plan should 
entail preventative measures and action plans to manage the 
power loss in order to facilitate a quick return to normal opera-
tion. Items to address include how to maintain critical opera-
tions (eg, computer systems), minimize inventory damage or 
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The purpose of the Attestation Form is to document the can-
didate’s completion of required training and certain skill and 
competency assessments in such areas as aseptic technique, 
equipment cleaning, and use of personal protective equip-
ment. More details about the CSPT Program are available on 
PTCB’s website at www.ptcb.org.
DEA Enables Mid-level Practitioners to 
Prescribe and Dispense Buprenorphine
In January 2018, DEA announced a deregulatory measure 
that will make it easier for residents of underserved areas to 
receive treatment for opioid addiction. Nurse practitioners 
and physician assistants can now become Drug Addiction 
Treatment Act-Waived qualifying practitioners, which gives 
them authority to prescribe and dispense the opioid main-
tenance drug buprenorphine from their offices. This final 
rule took effect January 22, 2018. More details about DEA’s 
amendments are available in a Federal Register notice titled 
“Implementation of the Provision of the Comprehensive Ad-
diction and Recovery Act of 2016 Relating to the Dispens-
ing of Narcotic Drugs for Opioid Use Disorder” (Document 
Number: 2018-01173).
New CDC Training Offers CPE on Antibiotic 
Stewardship
The Centers for Disease Control and Prevention’s 
(CDC’s) Office of Antibiotic Stewardship is offer-
ing free continuing education opportunities for health 
care professionals. Focused on judicious antibiotic pre-
scribing and antibiotic resistance, the online training is 
offered in four sections, each with multiple modules. 
Section 1 of the “CDC Training on Antibiotic Steward-
ship” is open now and can be accessed at www.train 
.org/cdctrain/course/1075730/compilation. Additional 
sections will be released throughout 2018. More information 
and resources about CDC’s national effort to help fight antibi-
otic resistance and improve antibiotic prescribing and use are 
available on CDC’s website at www.cdc.gov/antibiotic-use/
index.html. CDC is accredited by the Accreditation Council 
for Pharmacy Education (ACPE) as a provider of continuing 
pharmacy education (CPE). This program meets the criteria 
for 0.258 CEUs of CPE credit. The ACPE Universal Activity 
Number is 0387-0000-18-031-H05-P.
Walmart to Provide Free Solution to 
Dispose of Medications With Schedule II 
Prescriptions
In partnership with Walmart, DisposeRx will provide a 
safe and easy way to neutralize unused, unwanted, or expired 
prescription opioids. DisposeRx developed a powdered prod-
uct, also called DisposeRx, that permanently dissolves when 
mixed with water and sequesters excess opioids and other 
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DEA Launches New Tool to Help 
Distributors Make Informed Decisions 
About Customers
In February 2018, Drug Enforcement Administration 
(DEA) launched a new tool to assist drug manufacturers and 
distributors with their regulatory obligations under the Con-
trolled Substances Act. The agency added a new feature to 
its Automation of Reports and Consolidated Orders System 
(ARCOS) Online Reporting System, a comprehensive drug re-
porting system that monitors the flow of controlled substances 
(CS) from their point of manufacture through commercial 
distribution channels to the point of sale at the dispensing/
retail level. This newly added function will allow the more 
than 1,500 DEA-registered manufacturers and distributors to 
view the number of registrants who have sold a particular CS 
to a prospective customer in the last six months. 
DEA regulations require distributors to both “know their 
customer” and to develop a system to identify and report suspi-
cious orders. Manufacturers and distributors have asked DEA 
for assistance in fulfilling these obligations and have requested 
ARCOS information to help them determine if new customers 
are purchasing excessive quantities of CS. This new tool will 
provide valuable information for distributors to consider as 
part of their assessment. More details are available in a news 
release at www.dea.gov/divisions/hq/2018/hq021418.shtml.
PTCB Launches Certified Compounded 
Sterile Preparation Technician Program
In January 2018, the Pharmacy Technician Certification 
Board (PTCB) launched the PTCB Certified Compounded 
Sterile Preparation Technician (CSPT) Program. To be eligible 
to apply, a technician must:
♦ Be a PTCB certified pharmacy technician (CPhT) in
good standing; and
♦ Have completed either a PTCB-recognized sterile com-
pounding education/training program and one year of
continuous full-time compounded sterile preparation
work experience, or three years of continuous full-time
compounded sterile preparation work experience.
To earn CSPT Certification, eligible CPhTs are re-
quired to pass the CSPT Exam and submit compe-
tency attestation documentation from a qualified 
supervisor. The two-hour, 75-question CSPT Exam covers 
hazardous and nonhazardous compounded sterile products in 
the four domains of: 
♦ Medications and components (17%);
♦ Facilities and equipment (22%);
♦ Sterile compounding procedures (53%); and
♦ Handling, packaging, storage, and disposal (8%).
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drugs in a stiff, biodegradable gel that can be safely thrown 
in the trash. Walmart will provide a free packet of DisposeRx 
with every new Schedule II prescription filled at its 4,700 
pharmacies nationwide. “This partnership with DisposeRx is 
an exciting opportunity for Walmart to protect the safety of its 
customers and public health. Unwanted or expired prescrip-
tion medications left inside consumers’ medicine cabinets 
can be an easy source for those seeking to misuse or abuse a 
prescription drug,” said Pharmacy Clinical Services Manager 
for WalMart Health and Wellness and NABP Past President 
Jeanne D. Waggener, RPh, DPh. “We’re not just making it 
easy for patients to safely dispose of their medications, but 
we’re also helping prevent abuse before it starts.” Additional 
information is provided in a January 17, 2018 news release 
titled “Walmart Launches Groundbreaking Disposal Solution 
to Aid in Fight Against Opioid Abuse and Misuse.”
ASHP Research and Education Foundation 
Predicts Trends to Affect Pharmacy in 2018
In the 2018 Pharmacy Forecast: Strategic Planning 
Advice for Pharmacy Departments in Hospitals and 
Health Systems, the American Society of Health-System 
Pharmacists (ASHP) Research and Education Founda-
tion provides guidance on eight topics that will challenge 
pharmacy practice leaders in hospitals and health systems. 
Published in the January 15, 2018 issue of American 
Journal of Health-System Pharmacy, the new report focuses 
on the following areas: 
♦ Therapeutic innovation;
♦ Data, analytics, and technology;
♦ Business of pharmacy;
♦ Pharmacy and health-system leadership;
♦ Advanced pharmacy technician roles;
♦ Population health management;
♦ Public health imperatives; and
♦ Coping with uncertainty and chaos.
The 2018 report  is  available at  www.ajhp.org/
content/75/2/23.
USP Encourages Pharmacists to Help 
Patients Find Quality Dietary Supplements
Recall announcements, enforcement actions, and reports 
challenging the quality of dietary supplements are problem-
atic issues facing pharmacists who want to ensure that the 
over-the-counter (OTC) products they are recommending to 
patients are of good quality. Many consumers purchase OTC 
dietary supplements and herbal products, often assuming they 
are regulated like prescription medications. While the law 
requires pharmaceuticals to meet specific quality standards 
set by the United States Pharmacopeial Convention (USP), 
the same requirements do not apply to supplements. For this 
reason, USP has created quality standards and a verifica-
tion process specifically for these health products. Brands 
displaying the USP Verified Mark signal to the public that 
“what’s on their label is what’s in the bottle.” Health care 
practitioners can learn more about USP’s efforts at www.usp 
.org/dietary-supplements-herbal-medicines. 
Further, USP Dietary Supplement Verification Services 
are available to manufacturers and brands worldwide. They 
include Good Manufacturing Practice facility auditing, prod-
uct quality control and manufacturing product documentation 
review, and product testing. Manufacturers that are participat-
ing in USP’s verification program for dietary supplements 
can be found at www.usp.org/verification-services/program-
participants.
New CPE Monitor Subscription Plan 
Helps Pharmacists Track Compliance Via 
Mobile App
To help pharmacists easily monitor their CPE compliance, 
NABP partnered with the Accreditation Council for Pharmacy 
Education (ACPE) to develop CPE Monitor Plus, a subscrip-
tion service for CPE Monitor®. Launched in April 2018, the 
new subscription service enables pharmacists to perform a 
variety of advanced functions beyond the basic CPE Monitor 
service, including: 
♦ viewing CPE credit status by state to verify at a glance
how much CPE credit must be earned to satisfy license
renewal requirements;
♦ uploading certificates from non-ACPE CPE courses and 
applying them to relevant state licenses;
♦ receiving email alerts when CPE cycle deadlines are
approaching;
♦ viewing all transcripts and individual courses and gen-
erating simplified, automated reports;
♦ searching for additional ACPE activities via ACPE
P.L.A.N. (Pharmacists’ Learning Assistance Network);
and
♦ accessing ACPE CPD (Continuous Professional Devel-
opment) via single sign on.
CPE Monitor Plus is available for an annual, renewable 
subscription fee of $29.95, regardless of how many licenses 
a pharmacist has or adds at a later date. CPE Monitor Plus 
is only available via NABP’s new mobile app. Search for 
NABP e-Profile in Google Play Store (Android) or the App 
Store (iPhone). 
The standard CPE Monitor service is still available for free 
and can also be accessed via the app or a desktop by signing 
in with NABP e-Profile login credentials.
For more information, visit www.nabp.pharmacy/CPE.
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loss (refrigerated/frozen products), as well as staff education 
on these procedures. The pharmacist manager of record should 
review the plan with all relevant staff and post it in an easily 
accessible location. Pharmacies should also develop a commu-
nication plan with other pharmacies, prescribers, and caregivers 
to maintain continuity of care during this time period.
If the power loss is relatively short in duration and the 
temperature of the room is not extreme, staff should refrain 
from opening the refrigerator and freezer units. Once power 
is restored, it is imperative to monitor temperature readings to 
determine if the stored medications have been exposed to out 
of range temperatures. If refrigerator/freezer storage condi-
tions have been compromised and damage to the contents is 
suspected, the drug inventory must be evaluated for continued 
product integrity according to United States Pharmacopeia 
(USP) standards and Board policy.
The power loss may affect other systems and appliances 
within the pharmacy including the information technology 
system, telephones, automated dispensing systems, heating/
air-conditioning, diagnostic equipment, and alarm systems. It 
is strongly advised to utilize a portable generator or a backup 
generator and verify which automated devices and equipment 
are supported by that generator. Generators should be tested 
monthly and maintained on a regular basis.
Pharmacies that engage in sterile compounding are advised 
to provide an uninterruptible source of power or backup gen-
erator for the clean room air handlers and primary engineering 
controls. CriticalPoint, LLC, recommends having previously 
established baseline and excursion levels for temperature, hu-
midity, and nonviable particle count. The pharmacy should note 
the time of the power loss, limit access to the ISO controlled 
environments, and prevent introduction of additional sources 
of contamination to the compromised airflow. Once power is 
restored, the particulate counts should return to acceptable 
levels within 30 minutes, but pharmacies should maintain 
compliance with USP Chapter <797> requirements in regard to 
returning buffer rooms to 30 air changes per hour and tempera-
ture, humidity, and pressure differentials to acceptable ranges. 
A thorough cleaning of primary engineering controls as well as 
environmental monitoring should be performed in accordance 
with USP standards before resuming compounding activities.
Permitted Prescription Changes
The joint policy between the Drug Control Program and the 
Board that provides a list of changes and additions that phar-
macies are permitted to make on prescriptions was updated in 
March 2018. Although the majority of information has stayed 
the same, a few additions and clarifications have been made.
After consultation with the prescriber, information that may 
be changed or added to Schedule II prescriptions now includes 
the supervising physician’s name of a mid-level prescriber, “no 
substitution” language, and “partial fill upon patient request” 
language.
 After consultation with the prescriber or authorized agent, 
information that may be changed or added to Schedule III-VI 
prescriptions now includes the supervising physician’s name of 
a mid-level prescriber and “no substitution” language. Addition-
ally, the days supply (eg, 30-day versus 60-day supply) may 
be changed after authorization, but only for Schedule VI drugs 
that do not require prescription monitoring program reporting.
Learn more about the policy.
Lau Kwan’s Retirement
After 34 years of service, Lau Kwan, the Board’s beloved 
administrative assistant, has retired. Her last day with the Board 
was May 31, 2018. As an important contributor to many of the 
Board’s operations, Lau will be sorely missed around the office. 
In addition to her hard work, she was always friendly, helpful, 
and dedicated, and the Board will miss her pleasant disposition. 
Thank you and good luck, Lau!
Inquiries Received by the Board
In 2017, a total of 1,422 documented inquiries were received 
from stakeholders and the public. The average time of response 
to the inquirer, excluding outliers, was 40.31 hours and the 
median time was 24.26 hours. In addition to time required for 
research, the response times included non-business hours such 
as nights and weekends. The majority of the inquiries fell under 
the categories of licensing, nonresident licensing, controlled 
substances, continuing education, and general prescription 
questions.
Did You Know?
A quality-related event is defined as an improperly dispensed 
prescribed medication that includes any deviation from the 
prescription, including quantity errors. Incorrectly dispensed 
quantities of medications, including those of Schedule II drugs, 
should be added to the pharmacy’s continuous quality improve-
ment program for analysis.
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